RAET1E

RAET1E (ULBP4) is a stress-induced, transmembrane MHC class I-related glycoprotein that activates innate and adaptive immune effector cells by engaging the NKG2D/DAP10 activating receptor on NK cells and CD8+ T cells, and by directly binding TCRγ9/δ2 on γδ T cells (PMID:12732206, PMID:19436053). Unlike other ULBP family members that are GPI-anchored, RAET1E possesses a transmembrane domain and undergoes proteolytic shedding to generate soluble forms; an alternatively spliced soluble isoform (RAET1E2) downregulates NKG2D on NK cells and suppresses antitumor cytotoxicity, constituting an immune evasion mechanism (PMID:17470428, PMID:29651291). RAET1E engagement costimulates CD8+CD28− tumor-infiltrating lymphocytes by increasing glucose uptake and conferring resistance to Fas-mediated and cisplatin-induced apoptosis (PMID:15026360). In mouse models, the ortholog Raet1e functions as an atheroprotective gene expressed in aortic endothelial cells and macrophages, and transgenic overexpression reduces atherosclerosis in Apoe−/− mice (PMID:23948654).

1. 2003 High

   Identification of RAET1E as a functional NKG2D ligand established that the ULBP family includes a transmembrane member capable of activating NK cell cytotoxicity, resolving whether additional human NKG2D ligands existed beyond the known GPI-anchored ULBPs and MICs.

   Evidence Recombinant NKG2D binding assay and NK cytotoxicity assay using ULBP4-transduced EL4 cells

   PMID:12732206 PMID:14508119

   Open questions at the time

   • Crystal structure of ULBP4–NKG2D complex not determined
   • Physiological regulation of RAET1E surface expression undefined
   • Relative contribution of NKG2D versus other receptors in vivo unknown
2. 2004 Medium

   Demonstration that RAET1E costimulates CD8+CD28− tumor-infiltrating lymphocytes—enhancing glucose uptake, protecting from cisplatin-induced death, and downregulating Fas—revealed a metabolic and survival-reprogramming function beyond simple cytotoxicity activation.

   Evidence Ex vivo stimulation of TILs with Letal/ULBP4; glucose uptake, Fas expression, and apoptosis assays

   PMID:15026360

   Open questions at the time

   • Signaling pathway linking NKG2D engagement to Glut-1 upregulation not defined
   • In vivo relevance of TIL costimulation by ULBP4 not tested
   • Whether other NKG2D ligands produce identical metabolic effects unclear
3. 2007 High

   Discovery of a soluble splice isoform (RAET1E2) that downregulates NKG2D and suppresses NK cytotoxicity identified a tumor immune-evasion mechanism intrinsic to the RAET1E locus, answering how tumors might exploit NKG2D ligand biology without requiring shedding enzymes.

   Evidence RT-PCR cloning of RAET1E2 transcript; recombinant soluble RAET1E2 treatment of NK-92 cells; flow cytometry and cytotoxicity assays

   PMID:17470428

   Open questions at the time

   • Prevalence of RAET1E2 splice variant across tumor types not systematically assessed
   • Mechanism of NKG2D internalization/degradation upon soluble ULBP4 binding not elucidated
   • Whether RAET1E2 also engages TCRγδ unknown
4. 2009 High

   Demonstration that ULBP4 directly binds TCRγ9/δ2 and activates γδ T cells through both TCR and NKG2D established RAET1E as a dual-receptor ligand, expanding its immunological function beyond the NKG2D axis.

   Evidence Binding assay with soluble chimeric TCRγ9/δ2; Jurkat cell transfection with TCRγδ; blocking antibody epistasis; Vδ2+ T cell proliferation and cytotoxicity assays

   PMID:19436053

   Open questions at the time

   • Structural basis of ULBP4–TCRγ9/δ2 interaction unknown
   • Relative affinity of ULBP4 for NKG2D versus TCRγδ not quantified
   • In vivo contribution of γδ T cell activation by ULBP4 not demonstrated
5. 2013 High

   Genetic mapping and transgenic rescue in mice identified Raet1e as the causal atheroprotective gene at the Ath11 10b locus, revealing an unexpected cardiovascular role for an NKG2D ligand beyond cancer immunosurveillance.

   Evidence Subcongenic mapping in Apoe−/− mice; transgene-induced aortic Raet1e overexpression; promoter luciferase assay

   PMID:23948654

   Open questions at the time

   • Mechanism by which Raet1e reduces atherosclerosis (NKG2D-dependent or independent) not established
   • Whether human RAET1E has analogous vascular expression and function unknown
   • Immune cell types mediating the atheroprotective effect not identified
6. 2018 Medium

   Biochemical characterization showed that mature ULBP4 glycoprotein undergoes proteolytic shedding from the cell surface, establishing an additional post-translational route—besides alternative splicing—for generating soluble ULBP4 that could modulate NKG2D signaling.

   Evidence Biochemical glycoprotein analysis and proteolytic shedding assay of ULBP4-expressing cells

   PMID:29651291

   Open questions at the time

   • Identity of the protease(s) responsible for ULBP4 shedding not determined
   • Functional comparison of shed versus splice-derived soluble ULBP4 not performed
   • In vivo serum levels and clearance of shed ULBP4 not measured
7. 2021 Medium

   Soluble ULBP4 was shown to stimulate CD8+ T cell cytokine production and motility in the CNS context, and a shed 25-kDa form was elevated in CSF of female MS patients, linking RAET1E to neuroinflammation; simultaneously, the prior report of constitutive ULBP4 expression on monocytes was refuted by antibody validation with knockout controls.

   Evidence Primary CD8+ T cell functional assays with soluble ULBP4; astrocyte co-culture motility imaging; CSF Western blot from MS patients; RT-PCR and flow cytometry with ULBP4-knockout validation cells

   PMID:33556116 PMID:34873031

   Open questions at the time

   • Source of shed ULBP4 in the CNS not identified
   • Whether elevated CSF ULBP4 is causally related to MS pathology versus a bystander marker unclear
   • Antibody reagent issues highlight need for independent validation of ULBP4 tissue expression reports

• Key unresolved questions include the structural basis of ULBP4 recognition by both NKG2D and TCRγδ, the identity of sheddases acting on ULBP4, the signaling pathways downstream of ULBP4-mediated T cell costimulation, and whether the atheroprotective function of Raet1e translates to human cardiovascular biology.
• No crystal structure of ULBP4 alone or in complex with NKG2D or TCRγδ
• Sheddase identity unknown
• Human vascular expression and cardiovascular relevance not established